{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:00:11Z","timestamp":1790168411364,"version":"4.1.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:p>The integration of blood-based biomarkers and artificial intelligence (AI) is revolutionizing the diagnostic landscape of Alzheimer\u2019s disease (AD). In this paper, we synthesize recent advancements in the application of machine learning (ML) on blood biomarker analysis, evaluating their diagnostic efficacy and clinical translational potential. Current evidence identifies plasma p-tau217 as the best individual biomarker for primary screening. However, multiple biomarker signatures (such as A\/T\/N) combined with ML algorithms (like XGBoost) greatly improve diagnostic accuracy for mild cognitive impairment. Notably, predictive performance is maximized with multimodal fusion, which integrates data from blood, neuroimaging, and genetics, achieving an area under the curve of up to 0.94. To mitigate the black-box nature of these models, explainable AI frameworks like SHapley Additive exPlanations (SHAP) are essential for establishing clinical interpretability. Ultimately, we propose a scalable \u201cStep-Care\u201d framework that transitions from single-biomarker community screening to precise multimodal fusion, optimizing clinical trial stratification and personalized workflows.<\/jats:p>","DOI":"10.3389\/fnagi.2026.1937244","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:00:11Z","timestamp":1790164811000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Blood biomarkers and artificial intelligence: toward precision medicine in Alzheimer\u2019s disease"],"prefix":"10.3389","volume":"18","author":[{"given":"Linhong","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Neurology, Peking University First Hospital, Peking University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianbo","family":"Tu","sequence":"additional","affiliation":[{"name":"Health Service Department of the Guard Bureau of the Joint Staff Department","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jipeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Health Service Department of the Guard Bureau of the General Office of the Central Committee of the Communist Party of China","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Peking University First Hospital, Peking University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongan","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Neurology, Peking University First Hospital, Peking University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s13195-025-01851-2","article-title":"Optimizing timing and cost-effective use of plasma biomarkers in Alzheimer\u2019s disease.","volume":"17","author":"Chang","year":"2025","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/alz.12724","article-title":"Plasma A\u03b242\/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer\u2019s disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.","volume":"19","author":"Chatterjee","year":"2023","journal-title":"Alzheimer\u2019s Dement."},{"key":"B3","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13195-025-01801-y","article-title":"Predicting brain amyloid load with digital and blood-based biomarkers.","volume":"17","author":"Chen","year":"2025","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1021\/acschemneuro.2c00255","article-title":"Machine learning-based classification of subjective cognitive decline, mild cognitive impairment, and Alzheimer\u2019s dementia using neuroimage and plasma biomarkers.","volume":"13","author":"Chiu","year":"2022","journal-title":"ACS Chem. Neurosci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1021\/acschembio.4c00602","article-title":"Multimodal blood-based biomarker panel reveals altered lysosomal ionic content in Alzheimer\u2019s disease.","volume":"20","author":"Deivasigamani","year":"2025","journal-title":"ACS Chem. Biol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e14549","DOI":"10.1002\/alz.14549","article-title":"The dementia SomaSignal test (dSST): A plasma proteomic predictor of 20-year dementia risk.","volume":"21","author":"Duggan","year":"2025","journal-title":"Alzheimer\u2019s Dement."},{"key":"B7","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1109\/JBHI.2020.2984355","article-title":"Early detection of Alzheimer\u2019s disease with blood plasma proteins using support vector machines.","volume":"25","author":"Eke","year":"2021","journal-title":"IEEE J. Biomed. Health Inform."},{"key":"B8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41591-018-0316-z","article-title":"A guide to deep learning in healthcare.","volume":"25","author":"Esteva","year":"2019","journal-title":"Nat. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s40120-025-00741-x","article-title":"The cognivue amyloid risk measure (CARM): A novel method to predict the presence of amyloid with cognivue clarity.","volume":"14","author":"Galvin","year":"2025","journal-title":"Neurol. Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/alz.12700","article-title":"A combination model of AD biomarkers revealed by machine learning precisely predicts Alzheimer\u2019s dementia: China aging and neurodegenerative initiative (CANDI) study.","volume":"19","author":"Gao","year":"2023","journal-title":"Alzheimer\u2019s Dement."},{"key":"B11","doi-asserted-by":"publisher","first-page":"102172","DOI":"10.1016\/j.arr.2023.102172","article-title":"Machine learning in Alzheimer\u2019s disease drug discovery and target identification.","volume":"93","author":"Geng","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"B12","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13195-025-01785-9","article-title":"The economic burden of subjective cognitive decline, mild cognitive impairment and Alzheimer\u2019s dementia: Excess costs and associated clinical and risk factors.","volume":"17","author":"Gl\u00e4ser","year":"2025","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","article-title":"Blood biomarkers for Alzheimer\u2019s disease in clinical practice and trials.","volume":"3","author":"Hansson","year":"2023","journal-title":"Nat. Aging"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e70579","DOI":"10.1002\/alz.70579","article-title":"Plasma proteomic analysis identifies proteins and pathways related to Alzheimer\u2019s risk.","volume":"21","author":"Huang","year":"2025","journal-title":"Alzheimer\u2019s Dement."},{"key":"B15","doi-asserted-by":"publisher","first-page":"103142","DOI":"10.1016\/j.eclinm.2025.103142","article-title":"Development and validation of machine learning models with blood-based digital biomarkers for Alzheimer\u2019s disease diagnosis: A multicohort diagnostic study.","volume":"81","author":"Jiao","year":"2025","journal-title":"Eclinicalmedicine"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e14600","DOI":"10.1002\/alz.14600","article-title":"Machine learning prediction of tau-PET in Alzheimer\u2019s disease using plasma, MRI, and clinical data.","volume":"21","author":"Karlsson","year":"2025","journal-title":"Alzheimer\u2019s Dement."},{"key":"B17","doi-asserted-by":"publisher","first-page":"116128","DOI":"10.1016\/j.bios.2024.116128","article-title":"Surface-functionalized SERS platform for deep learning-assisted diagnosis of Alzheimer\u2019s disease.","volume":"251","author":"Kim","year":"2024","journal-title":"Biosens. Bioelectron."},{"key":"B18","doi-asserted-by":"publisher","first-page":"7698","DOI":"10.1002\/alz.14230","article-title":"Plasma miRNAs across the Alzheimer\u2019s disease continuum: Relationship to central biomarkers.","volume":"20","author":"Liu","year":"","journal-title":"Alzheimer\u2019s Dement."},{"key":"B19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40035-024-00397-x","article-title":"The interaction between ageing and Alzheimer\u2019s disease: Insights from the hallmarks of ageing.","volume":"13","author":"Liu","year":"","journal-title":"Transl. Neurodegener."},{"key":"B20","doi-asserted-by":"publisher","first-page":"100209","DOI":"10.1016\/j.cmpbup.2025.100209","article-title":"Predicting Alzheimer\u2019s disease onset: A machine learning framework for early diagnosis using biomarker data.","volume":"8","author":"Mohammed","year":"2025","journal-title":"Comput. Methods Programs Biomed. Update"},{"key":"B21","doi-asserted-by":"publisher","first-page":"8700","DOI":"10.1002\/alz.14319","article-title":"Assessing polyomic risk to predict Alzheimer\u2019s disease using a machine learning model.","volume":"20","author":"Ngai","year":"2024","journal-title":"Alzheimer\u2019s Dement."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","article-title":"Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: An analysis for the global burden of disease study 2019.","volume":"7","author":"Nichols","year":"2022","journal-title":"Lancet Public Health"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.3390\/cells13221920","article-title":"A transcriptomics-based machine learning model discriminating mild cognitive impairment and the prediction of conversion to Alzheimer\u2019s disease.","volume":"13","author":"Park","year":"2024","journal-title":"Cells"},{"key":"B25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.14283\/jpad.2018.41","article-title":"Plasma A\u03b242\/40 ratio detects early stages of Alzheimer\u2019s disease and correlates with CSF and neuroimaging biomarkers in the AB255 study.","volume":"6","author":"P\u00e9rez-Grijalba","year":"2019","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13195-022-01051-2","article-title":"Inflammatory plasma biomarkers in subjects with preclinical Alzheimer\u2019s disease.","volume":"14","author":"Prins","year":"2022","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1038\/s41467-022-31037-5","article-title":"Multimodal deep learning for Alzheimer\u2019s disease dementia assessment.","volume":"13","author":"Qiu","year":"2022","journal-title":"Nat Commun."},{"key":"B28","doi-asserted-by":"publisher","first-page":"100630","DOI":"10.1016\/j.lanhl.2024.07.013","article-title":"Challenges in the practical implementation of blood biomarkers for Alzheimer\u2019s disease.","volume":"5","author":"Sch\u00f6ll","year":"2024","journal-title":"Lancet Healthy Longev."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1038\/s41591-023-02505-2","article-title":"Emerging diagnostics and therapeutics for alzheimer disease.","volume":"29","author":"Self","year":"2023","journal-title":"Nat. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1177\/13872877241306654","article-title":"Predicting cognitive decline from neuropsychiatric symptoms and Alzheimer\u2019s disease biomarkers: A machine learning approach to a population-based data.","volume":"103","author":"Shah","year":"2025","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1571429","DOI":"10.3389\/fnagi.2025.1571429","article-title":"Virtual reality navigation for the early detection of Alzheimer\u2019s disease.","volume":"17","author":"Shima","year":"2025","journal-title":"Front. Aging Neurosci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.jalz.2019.03.009","article-title":"Plasma amyloid \u03b2 40\/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer\u2019s disease.","volume":"15","author":"Vergallo","year":"2019","journal-title":"Alzheimer\u2019s &amp; Dementia"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e70060","DOI":"10.1002\/trc2.70060","article-title":"Predictive value and weight of factors associated with cognitive performance in hispanics\/latinos enrolled in the health and aging brain study: Health disparities.","volume":"11","author":"Vintimilla","year":"2025","journal-title":"Alzheimer\u2019s Dement: Transl. Res. Clin. Interv."},{"key":"B34","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/jrsm.1080","article-title":"Quality assessment of comparative diagnostic accuracy studies: Our experience using a modified version of the QUADAS-2 tool.","volume":"4","author":"Wade","year":"2013","journal-title":"Res. Synth. Method"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.3390\/ijms26062428","article-title":"Comparison of deep learning and traditional machine learning models for predicting mild cognitive impairment using plasma proteomic biomarkers.","volume":"26","author":"Wang","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies.","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann. Intern. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"106356","DOI":"10.1016\/j.nbd.2023.106356","article-title":"Trajectories of CSF and plasma biomarkers across Alzheimer\u2019s disease continuum: Disease staging by NF-L, p-tau181, and GFAP.","volume":"189","author":"Wojda\u0142a","year":"2023","journal-title":"Neurobiol. Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"51","DOI":"10.7326\/M18-1376","article-title":"PROBAST: A tool to assess the risk of bias and applicability of prediction model studies.","volume":"170","author":"Wolff","year":"2019","journal-title":"Ann. Intern. Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s12911-022-02024-z","article-title":"Prediction of amyloid PET positivity via machine learning algorithms trained with EDTA-based blood amyloid-\u03b2 oligomerization data.","volume":"22","author":"Youn","year":"2022","journal-title":"BMC Med. Inf. Decis. Making"},{"key":"B40","doi-asserted-by":"publisher","first-page":"112535","DOI":"10.1016\/j.exger.2024.112535","article-title":"Tau pathology mediated the plasma biomarkers and cognitive function in patients with mild cognitive impairment.","volume":"195","author":"Zhao","year":"2024","journal-title":"Exp. Gerontol."}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2026.1937244\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:00:12Z","timestamp":1790164812000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2026.1937244\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":40,"alternative-id":["10.3389\/fnagi.2026.1937244"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2026.1937244","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"article-number":"1937244"}}